A dipeptidyl peptidase-IV inhibitor improves hepatic steatosis and insulin resistance by AMPK-dependent and JNK-dependent inhibition of LECT2 expression

Keyphrases

• C-Jun N-terminal Kinase 100%
• AMP-activated Protein Kinase 100%
• Insulin Resistance 100%
• Hepatic Steatosis 100%
• Dipeptidyl peptidase-4 (DPP-4) 100%
• Leukocyte Cell-derived Chemotaxin 2 (LECT2) 100%
• Gemigliptin 80%
• Non-alcoholic Fatty Liver Disease (NAFLD) 30%
• Tumor Necrosis Factor-α 20%
• Phosphorylation 20%
• Mammalian Target of Rapamycin (mTOR) 20%
• HepG2 Cells 20%
• Lipid Accumulation 20%
• Protein Kinase Inhibitors 20%
• High-fat Diet 20%
• Sterol Regulatory Element-binding protein-1c (SREBP-1c) 20%
• AMP-activated Protein Kinase Phosphorylation 20%
• High-fat Diet Mice 20%
• Western Blot 10%
• C57BL 10%
• Novel Therapeutics 10%
• Liver Tissue 10%
• Knockdown 10%
• Akt Phosphorylation 10%
• HepG2 Cell Line 10%
• Obesity 10%
• Protective Effect 10%
• In Vivo Experiment 10%
• Insulin Receptor Substrate 1 (IRS1) 10%
• Inflammatory Disorders 10%
• Jun N-terminal Kinase Inhibitor 10%
• Disease Pathogenesis 10%
• Metabolic Disturbances 10%
• Liver Disease Progression 10%
• Hepatokine 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Phosphotransferase 100%
• Insulin Resistance 100%
• Fatty Liver 100%
• Hydroxymethylglutaryl Coenzyme A Reductase Kinase 100%
• Dipeptidyl Peptidase IV Inhibitor 100%
• Chemotaxin 100%
• Gemigliptin 80%
• Nonalcoholic Fatty Liver 30%
• Tumor Necrosis Factor 20%
• Mammalian Target of Rapamycin 20%
• Sterol Regulatory Element Binding Protein 1 20%
• Disease 10%
• Phosphotransferase Inhibitor 10%
• Western Blot 10%
• C57BL 6 Mouse 10%
• Metabolic Disorder 10%
• Protein Kinase Inhibitor 10%
• Disease Exacerbation 10%
• Insulin Receptor Substrate 1 10%